Xiao-Peng Lu
Overview
Explore the profile of Xiao-Peng Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo H, Dong N, Hu Y, Qiu J, Jiang Z, Liu Q, et al.
Front Nutr
. 2025 Mar;
12:1523426.
PMID: 40051966
Purpose: This study aims to compare the difference in serum high-density lipoprotein cholesterol (HDL-C) levels between children with epilepsy and healthy children and to assess its potential influencing factors. Methods:...
2.
Lu X, Jiang L, Li Y, Hou P, Xu J, Zhou X, et al.
J Agric Food Chem
. 2025 Feb;
73(10):6205-6214.
PMID: 39998841
is a highly destructive pest of stored grains worldwide. To develop novel RNA insecticides, the double-stranded RNA of cytochrome c oxidase (dss: dsI, dsII, and dsIII) was successfully expressed in...
3.
Zhang M, Wu D, Yu L, Li H, Sun D, Liang J, et al.
World J Pediatr
. 2025 Jan;
21(2):149-158.
PMID: 39745620
Background: Glucose transporter 1 deficiency syndrome (Glut1DS) was initially reported by De Vivo and colleagues in 1991. This disease arises from mutations in the SLC2A1 and presents with a broad...
4.
Li Y, Guo H, Wang J, Zhang Y, Wang W, Huang J, et al.
Ther Adv Neurol Disord
. 2024 Sep;
17:17562864241273087.
PMID: 39314259
Background: The widespread clinical use of lacosamide (LCM) has revealed significant individual differences in clinical response, with various reported influencing factors. However, it remains unclear how genetic factors related to...
5.
Li Y, Guo H, Hu Y, Wang J, Zhang Y, Huang J, et al.
Epilepsia Open
. 2023 Nov;
9(1):268-277.
PMID: 37943144
Objective: To evaluate the effectiveness and safety of perampanel (PER) monotherapy (MT) or add-on therapy (AT) in Chinese children with epilepsy, as well as to evaluate the data from routine...
6.
Ding L, Huang T, Ying G, Wang S, Xu H, Qian H, et al.
World J Clin Cases
. 2023 Jun;
11(14):3340-3350.
PMID: 37274027
Background: Early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1 (PEBEL1) is a rare autosomal recessive severe neurometabolic disease. The aim of this study was to investigate the clinical characteristics and...
7.
Wang J, Zhang Y, Guo H, Hu Y, Lu X, Wang S, et al.
Anal Methods
. 2023 Feb;
15(10):1365-1377.
PMID: 36847418
Vigabatrin is one of the second-generation anti-seizure medications (ASMs) designated orphan drugs by the FDA for monotherapy for pediatric patients with infantile spasms from 1 month to 2 years of...
8.
Guo H, Wang W, Dong N, Zhao Y, Dai H, Hu Y, et al.
Epilepsia Open
. 2023 Feb;
8(2):466-478.
PMID: 36808532
Objective: The drug-refractory epilepsy (DRE) in children is commonly observed but the underlying mechanisms remain elusive. We examined whether fatty acids (FAs) and lipids are potentially associated with the pharmacoresistance...
9.
Li Y, Dong N, Qin Y, Dai H, Hu Y, Zhao Y, et al.
Epilepsia Open
. 2022 Sep;
7(4):737-746.
PMID: 36177517
Objective: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was...
10.
Li Y, Guo H, Zhang Y, Dong N, Hu Y, Chen J, et al.
Front Pediatr
. 2022 Sep;
10:949783.
PMID: 36160782
Background: Lacosamide (LCM) is a newer anti-seizure medication (ASM) that was approved in China in 2018, but its real-world clinical data and plasma concentrations in Chinese children with epilepsy are...